Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer

被引：0
|
作者：
Bersanelli, Melissa [1 ]
Tiseo, Marcello [1 ]
Banna, Giuseppe L. [2 ]
机构：
[1] Univ Parma, Parma, Italy
[2] United Lincolnshire Hosp NHS Trust, Lincoln, England
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 382卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：874 / 875
页数：2
相关论文
共 50 条
  • [21] Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
    Tina Cascone
    William N. William
    Annikka Weissferdt
    Cheuk H. Leung
    Heather Y. Lin
    Apar Pataer
    Myrna C. B. Godoy
    Brett W. Carter
    Lorenzo Federico
    Alexandre Reuben
    Md Abdul Wadud Khan
    Hitoshi Dejima
    Alejandro Francisco-Cruz
    Edwin R. Parra
    Luisa M. Solis
    Junya Fujimoto
    Hai T. Tran
    Neda Kalhor
    Frank V. Fossella
    Frank E. Mott
    Anne S. Tsao
    George Blumenschein
    Xiuning Le
    Jianjun Zhang
    Ferdinandos Skoulidis
    Jonathan M. Kurie
    Mehmet Altan
    Charles Lu
    Bonnie S. Glisson
    Lauren Averett Byers
    Yasir Y. Elamin
    Reza J. Mehran
    David C. Rice
    Garrett L. Walsh
    Wayne L. Hofstetter
    Jack A. Roth
    Mara B. Antonoff
    Humam Kadara
    Cara Haymaker
    Chantale Bernatchez
    Nadim J. Ajami
    Robert R. Jenq
    Padmanee Sharma
    James P. Allison
    Andrew Futreal
    Jennifer A. Wargo
    Ignacio I. Wistuba
    Stephen G. Swisher
    J. Jack Lee
    Don L. Gibbons
    Nature Medicine, 2021, 27 : 504 - 514
  • [22] Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
    Cascone, Tina
    William, William N., Jr.
    Weissferdt, Annikka
    Leung, Cheuk H.
    Lin, Heather Y.
    Pataer, Apar
    Godoy, Myrna C. B.
    Carter, Brett W.
    Federico, Lorenzo
    Reuben, Alexandre
    Khan, Md Abdul Wadud
    Dejima, Hitoshi
    Francisco-Cruz, Alejandro
    Parra, Edwin R.
    Solis, Luisa M.
    Fujimoto, Junya
    Tran, Hai T.
    Kalhor, Neda
    Fossella, Frank V.
    Mott, Frank E.
    Tsao, Anne S.
    Blumenschein, George, Jr.
    Le, Xiuning
    Zhang, Jianjun
    Skoulidis, Ferdinandos
    Kurie, Jonathan M.
    Altan, Mehmet
    Lu, Charles
    Glisson, Bonnie S.
    Byers, Lauren Averett
    Elamin, Yasir Y.
    Mehran, Reza J.
    Rice, David C.
    Walsh, Garrett L.
    Hofstetter, Wayne L.
    Roth, Jack A.
    Antonoff, Mara B.
    Kadara, Humam
    Haymaker, Cara
    Bernatchez, Chantale
    Ajami, Nadim J.
    Jenq, Robert R.
    Sharma, Padmanee
    Allison, James P.
    Futreal, Andrew
    Wargo, Jennifer A.
    Wistuba, Ignacio I.
    Swisher, Stephen G.
    Lee, J. Jack
    Gibbons, Don L.
    NATURE MEDICINE, 2021, 27 (03) : 504 - +
  • [23] Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
    Borghaei, H.
    Ciuleanu, T. -E.
    Lee, J. -S
    Pluzanski, A.
    Caro, R. Bernabe
    Gutierrez, M.
    Ohe, Y.
    Nishio, M.
    Goldman, J.
    Ready, N.
    Spigel, D. R.
    Ramalingam, S. S.
    Paz-Ares, L. G.
    Gainor, J. F.
    Ahmed, S.
    Reck, M.
    Maio, M.
    O'Byrne, K. J.
    Memaj, A.
    Nathan, F.
    Tran, P.
    Hellmann, M. D.
    Brahmer, J. R.
    ANNALS OF ONCOLOGY, 2023, 34 (02) : 173 - 185
  • [24] Duration of nivolumab for pretreated, advanced non-small-cell lung cancer
    Geier, Margaux
    Descourt, Renaud
    Corre, Romain
    Leveiller, Guillaume
    Lamy, Regine
    Goarant, Eric
    Bizec, Jean-Louis
    Bernier, Cyril
    Quere, Gilles
    Amrane, Karim
    Gaye, Elisabeth
    Lucia, Francois
    Burte, Emilie
    Chouaid, Christos
    Robinet, Gilles
    CANCER MEDICINE, 2020, 9 (19): : 6923 - 6932
  • [25] Nivolumab in HIV-related non-small-cell lung cancer
    Hentrich, M.
    Schipek-Voigt, K.
    Jager, H.
    Schulz, S.
    Schmid, P.
    Stotzer, O.
    Bojko, P.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2890 - 2890
  • [26] Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab
    Mouri, Atsuto
    Watanabe, Satoshi
    Tokito, Takaaki
    Nagai, Yoshiaki
    Saida, Yu
    Imai, Hisao
    Yamaguchi, Ou
    Kobayashi, Kunihiko
    Kaira, Kyoichi
    Kagamu, Hiroshi
    CANCERS, 2024, 16 (07)
  • [27] Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
    Yang, Szu-Chun
    Kunst, Natalia
    Gross, Cary P.
    Wang, Jung-Der
    Su, Wu-Chou
    Wang, Shi-Yi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [28] Nivolumab plus chemotherapy for non-small cell lung cancer
    Lichert, Frank
    PNEUMOLOGIE, 2024, 78 (02): : 81 - 81
  • [29] Gefitinib plus clocetaxel in non-small-cell lung cancer
    Zalcman, Gerard
    Bergot, Emmanuel
    LANCET, 2009, 373 (9663): : 541 - 541
  • [30] Docetaxel plus cisplatin in non-small-cell lung cancer
    Chandra Belani
    Sakkaraiappan Ramalingam
    Vassilis Georgoulias
    George Simon
    Drugs & Therapy Perspectives, 2004, 20 (3) : 7 - 9
12345